AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00275054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cycles 1-6: 250 mg/m² i.v., d2-4, q28d
Study NCT00275054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: cycle1: 375 mg/m² i.v., d1, q28d~cycles 2-6: 500 mg/m² i.v., d1, q28d
Study NCT03611764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan
Description: -All efforts will be made to normalize their experience: for example, the desire to open their eyes, thinking about other things, wanting to move around - these are all normal and participants will be encouraged to become interested in and curious about, and to allow these natural tendencies
Study NCT03611764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotterdam Symptom Checklist
Description: * 39 Likert-scale items, including physical and psychological symptoms (30 questions), daily function (8 questions), and overall valuation of life (one question)~* For the 30 questions pertaining to symptoms, the four-item Likert scale ranges from 'not at all=1' to 'very much=4'; the higher the total score, the greater the score, the higher the level of distress. The single question pertaining to overall valuation of life asks participants to circle one of the seven items, ranked from extremely poor to excellent
Study NCT03611764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Logs
Description: -Describe frequency of the Zen Den
Study NCT01357135 — intervention group
Intervention type: DRUG
Intervention: Sulfonylurea
Study NCT01357135 — intervention group
Intervention type: DRUG
Intervention: Antihyperglycemic Medication
Study NCT01510145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% BAK-free
Description: Containing Polyquad (PQ) preservative
Study NCT00617773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu3S193
Description: 20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
Study NCT00836290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Release (Group 1)
Description: Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
Study NCT00836290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-release (Group 2)
Description: Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
Study NCT02425046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coaching
Description: Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
Study NCT02425046 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: community screening
Description: Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
Study NCT02425046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community screening
Description: Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
Study NCT02631174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithrombin III
Description: We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
Study NCT03654170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 mixed with [C-14] BI425809
Description: Oral Solution
Study NCT03220074 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral Tablet
Description: study drug given and monitored for efficacy and tolerability
Study NCT04207736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.
Study NCT04207736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.
Study NCT02329704 — intervention group
Intervention type: PROCEDURE
Intervention: Diff-Quik staining for morphology evaluation
Description: Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).~Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm.
Study NCT02329704 — intervention group
Intervention type: PROCEDURE
Intervention: Motility Evaluation for grade A and B
Description: The better separation method will insure more progressive sperms after processing.~Grading using A and B scale scored by (WHO 2010) references.
Study NCT02329704 — intervention group
Intervention type: PROCEDURE
Intervention: Concentration (mil/ml)
Description: count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
Study NCT02833090 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: biomarkers
Description: transthoracic echocardiography, radial, and aortic arterial blood sampling
Study NCT02833090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biomarkers
Description: transthoracic echocardiography, radial, and aortic arterial blood sampling
Study NCT03424967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABM
Description: Participants are trained with a dot-probe task including angry-neutral faces. In 80% of trials the probe appears in place of the neutral face, and in 20% of trials in place of the angry face.
Study NCT02272920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
Study NCT01529255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine (ROADMAP)
Description: Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial.
Study NCT01368692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: position of shoulder retraction
Description: position of shoulder retraction by placing a saline bag between the scapula
Study NCT02329704 — intervention group
Intervention type: PROCEDURE
Intervention: 24 H half life
Description: percentage of active motile to non motile sperms.~Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile.
Study NCT02329704 — intervention group
Intervention type: PROCEDURE
Intervention: 48 H half life
Description: percentage of active motile to non motile sperms.~Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile.
Study NCT01368692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: position of neutral shoulder
Description: neutral shoulder position during subclavian vein catheterization
Study NCT01529255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine (Standard of Care)
Description: Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial.
Study NCT03684811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102
Description: FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
Study NCT01215643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally
Study NCT01215643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study NCT01215643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study NCT01215643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
Study NCT01215643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
Study NCT00284557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based behavioral intervention
Description: The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter.
Study NCT00284557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based behavioral intervention
Description: The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter.
Study NCT03723720 — intervention group
Intervention type: DEVICE
Intervention: Colonoscopy
Description: Endoscopic examination of large bowel
Study NCT04576039 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: saline infusion sonography
Description: Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.
Study NCT02596958 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
Study NCT03372434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Intraocular Lens Device #1: Model ZFR00
Description: IOL replaces the natural lens removed during cataract surgery.
Study NCT03372434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Intraocular Lens Device #1: Model ZYR00
Description: IOL replaces the natural lens removed during cataract surgery.
Study NCT03372434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TECNIS Multifocal Intraocular Lens: Model ZLB00
Description: IOL replaces the natural lens removed during cataract surgery.
Study NCT01007929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-AZD1236
Description: Oral solution 1mg/mL
Study NCT00082706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
Study NCT00082706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
Study NCT00082706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
Study NCT00082706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Day: 1 \& 5 Dose: 200 mg/m2 (Two doses only)
Study NCT03165240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Film-coated tablet
Study NCT03165240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Film-coated tablet
Study NCT03165240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study NCT01537159 — intervention group
Intervention type: DEVICE
Intervention: 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system
Description: Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
Study NCT02348879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 403
Description: AMG 403 is for treatment of subjects with chronic pain
Study NCT02348879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains no active drug
Study NCT01530035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical training
Description: training
Study NCT01530035 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physical training
Description: training
Study NCT02421406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Behavioral Intervention
Description: A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
Study NCT02421406 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Education Intervention
Description: A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
Study NCT03297073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form
Study NCT03297073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic surgery
Study NCT01707433 — intervention group
Intervention type: OTHER
Intervention: Enzyme testing
Description: Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
Study NCT01073397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
Study NCT01073397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
Study NCT04037631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic device
Description: Diagnostic test
Study NCT00646321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (Symbicort)
Study NCT00646321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Study NCT01081704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab
Description: Single dose of 45 mg subcutaneous injection
Study NCT01081704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab
Description: Single dose of 90 mg subcutaneous injection
Study NCT03114579 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative heart rate measurement (reference method)
Description: Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)
Study NCT03114579 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NEXFIN HD
Study NCT05296824 — intervention group
Intervention type: PROCEDURE
Intervention: Cryoballoon ablation for the treatment of atrial fibrillation
Description: Cryoballoon ablation for the treatment of atrial fibrillation
Study NCT00052611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT01327079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated.
Study NCT00963716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hot biopsy forceps
Description: Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
Study NCT00963716 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold biopsy forceps
Description: Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
Study NCT00643786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygène
Description: Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
Study NCT00643786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Air Médical
Description: Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
Study NCT00063895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00063895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00063895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study NCT00063895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03684811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered per the site's standard of care.
Study NCT03684811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered per the site's standard of care.
Study NCT03684811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin
Description: Gemcitabine and cisplatin will be administered per the site's standard of care.
Study NCT03445338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study
Study NCT00766948 — intervention group
Intervention type: OTHER
Intervention: There is no intervention, this is a biorepository.
Description: There are no interventions in this study.
Study NCT03764189 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microosteoperforation
Description: small holes made using large round bur
Study NCT02177305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.02 mcg tiotropium solution
Study NCT02177305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.04 mcg tiotropium solution
Study NCT02177305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.08 mcg tiotropium solution
Study NCT02177305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.16 mcg tiotropium solution
Study NCT02177305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.28 mcg tiotropium solution
Study NCT02177305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.40 mcg tiotropium solution
Study NCT02177305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution